Paradigm Capital Management Inc. NY Acquires New Shares in MiMedx Group, Inc $MDXG

Paradigm Capital Management Inc. NY acquired a new position in shares of MiMedx Group, Inc (NASDAQ:MDXG) in the second quarter, Holdings Channel reports. The institutional investor acquired 4,073,100 shares of the company’s stock, valued at approximately $15,681,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Sunbelt Securities Inc. acquired a new stake in shares of MiMedx Group in the first quarter valued at $42,000. E Fund Management Co. Ltd. acquired a new position in MiMedx Group during the 2nd quarter worth about $45,000. Kemnay Advisory Services Inc. purchased a new position in MiMedx Group during the 4th quarter valued at about $48,000. Williams & Novak LLC purchased a new position in MiMedx Group during the 2nd quarter valued at about $53,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in MiMedx Group in the 1st quarter valued at about $65,000. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

MDXG has been the topic of several research reports. Seaport Research Partners cut shares of MiMedx Group to a “neutral” rating in a research report on Monday, August 17th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of MiMedx Group in a research note on Thursday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and set a $8.00 target price on shares of MiMedx Group in a report on Monday, August 17th. Raymond James Financial set a $8.00 target price on shares of MiMedx Group in a report on Monday, August 17th. Finally, Citizens Jmp decreased their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research report on Thursday, April 30th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $8.43.

MiMedx Group Stock Down 1.4%

MDXG stock opened at $4.27 on Tuesday. The company’s 50 day moving average price is $4.12 and its 200 day moving average price is $4.11. The firm has a market capitalization of $622.40 million, a price-to-earnings ratio of 106.78 and a beta of 1.45. MiMedx Group, Inc has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.79 and a current ratio of 5.33.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. The company had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. On average, equities research analysts anticipate that MiMedx Group, Inc will post -0.1 EPS for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.